DEVELOPMENT OF NEW ANTI-FELINE LEUKEMIA VIRUS DRUGS

描述：（改编自申请人摘要）。 协同 与新墨西哥州大学医学院的研究人员一起进行的研究 医学，主要研究者已经获得了关于 天然产物棉酚衍生物的抗病毒性质。 在 特别是，一种名为GIL的衍生物在抗肿瘤方面显示出有希望的活性。 治疗感染猫白血病病毒（FeLV）的家猫。 同样值得注意的是，GIL显示出有希望的体外活性 针对艾滋病病毒HIV-1，这表明GIL和其他衍生物 棉酚可能具有广谱抗病毒活性。 第一阶段申请的具体目的是进行一项受控的 GIL抗猫白血病病毒的临床研究 感染的猫。 这一阶段的研究旨在：1）确认 GIL的初步结果，使用了更大的动物种群， 在受控条件下; 2）获得与 GIL的毒性。

DESCRIPTION: (Adapted from the Applicant's Abstract). In collaborative studies with investigators at the University of New Mexico School of Medicine, the Principal Investigator has obtained preliminary data on the antiviral properties of derivatives of the natural product gossypol. In particular, one derivative named GIL has shown promising activity in the treatment of domestic cats infected with feline leukemia virus (FeLV). Also noteworthy is the fact that GIL shows promising in vitro activity against the AIDS virus, HIV-1, suggesting that GIL and other derivatives of gossypol may have broad spectrum antiviral activities. The specific aim of this Phase I application is to conduct a controlled clinical study of the effectiveness of GIL against feline leukemia virus in infected cats. This phase of the research is designed: 1) to confirm the preliminary results with GIL, using a larger population of animals under controlled conditions; 2) to obtain clinical data pertaining to the toxicity of GIL.